CHMP Backs Both High-Dose Wegovy HD and Oral Semaglutide for EU Approval — What the Twin Opinions Mean for the Research Landscape

Key takeaways

• On 22 May 2026, the CHMP adopted simultaneous positive opinions recommending EU marketing authorisation for Wegovy HD (semaglutide 7.2 mg, single-dose pen) and the Wegovy pill (oral semaglutide 25 mg).
• The injectable 7.2 mg formulation is already available in the EU dosed as three separate 2.4 mg injections; the new single-dose pen simplifies administration and awaits a formal European Commission decision expected to trigger a Q3 2026 EU launch.
• Wegovy HD 7.2 mg received MHRA authorisation in January 2026 and is already available in the UK through private providers; the oral pill remains under MHRA review, with a decision anticipated in late 2026 at the earliest.
• The dysesthesia signal identified at the higher dose warrants attention in any research context using semaglutide at supratherapeutic concentrations.
• Oral peptide-drug bioavailability remains a technically complex procurement consideration — the 25 mg oral dose is markedly higher than the 2.4 mg injectable dose, reflecting fundamentally different absorption kinetics.

The CHMP rulings in detail

On 22 May 2026, Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) had adopted two distinct positive opinions on the same day — one for a higher-dose injectable formulation and one for an oral formulation of semaglutide.

Wegovy HD 7.2 mg (injectable, single-dose pen). The CHMP recommended marketing authorisation for once-weekly semaglutide 7.2 mg delivered in a single-dose pen for adults living with obesity. The formulation was already available in the EU dosed as three consecutive 2.4 mg injections, authorised following an earlier European Commission decision in late 2025. The new single-dose pen device — already marketed in the United States as Wegovy HD since FDA approval on 19 March 2026 — simplifies the dosing process and Novo Nordisk expects an EU launch in Q3 2026, pending a formal European Commission decision.

Wegovy pill (oral semaglutide 25 mg, once daily). The CHMP simultaneously recommended authorisation for an oral formulation of semaglutide at 25 mg once daily. This is the first oral GLP-1 receptor agonist therapy recommended for approval by the CHMP for weight management in the EU. The positive opinion includes SELECT cardiovascular outcomes data in the proposed label, and the recommended label carries no drug-drug restrictions, meaning no limitations on concomitant medications — a feature Novo Nordisk has highlighted as a clinical differentiator. Novo Nordisk plans to launch the Wegovy pill in select markets outside the US in the second half of 2026, subject to European Commission ratification — a step that typically follows a positive CHMP opinion before formal marketing authorisation is granted.

STEP UP and OASIS: the evidence base

The 7.2 mg injectable dose is supported by the STEP UP Phase 3 trial programme. In the 72-week STEP UP trial, semaglutide 7.2 mg once weekly demonstrated 20.7% mean weight loss in approximately 1,400 adults with obesity, with around one in three participants achieving 25% or greater weight loss. In the companion STEP UP T2D trial, in adults with obesity and type 2 diabetes, the higher dose produced a mean weight loss of 14.1%. Over 89% of participants on 7.2 mg achieved at least 5% body weight loss, versus 38% on placebo. For context, the standard 2.4 mg injectable dose produces approximately 15% mean weight loss, meaning the 7.2 mg formulation represents an approximate six-percentage-point increment.

The oral pill recommendation rests on the OASIS trial programme. OASIS 4 was a 64-week Phase 3b trial of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity or overweight with one or more comorbidities; the broader OASIS programme informed the overall evidence package. At week 64, participants on the active treatment lost an average of 13.6% of their body weight compared with 2.2% on placebo, and around 30% of adherent participants achieved at least a 20% reduction in body weight. The SELECT2 cardiovascular outcomes data is incorporated into the recommended label.

The dysesthesia signal

Research procurement teams should note a safety signal that emerged at the higher injectable dose. In the STEP UP trial, dysesthesia and related altered skin-sensation symptoms occurred in 22% of participants on the 7.2 mg dose, compared with 6% on the 2.4 mg dose and 0.3% on placebo. The FDA is investigating; symptoms often resolved or improved with dose reduction. The overall safety and tolerability profile of the higher dose was otherwise described as consistent with that of the approved 2.4 mg dose, with gastrointestinal adverse events remaining the predominant class effect.

UK regulatory position

The two formulations are at different stages of UK review. Wegovy HD 7.2 mg received MHRA authorisation on 12 January 2026 and is the highest semaglutide dose currently licensed in the UK, available through private providers immediately upon licensing. The oral 25 mg formulation is on a separate trajectory: Novo Nordisk submitted the oral semaglutide application to the MHRA in the second half of 2025, and as of May 2026 the application remains under review, with a regulatory decision expected in late 2026. If approval is granted on that timeline, private launch is likely in late 2026 or early 2027.

Post-Brexit, MHRA assessments proceed independently of EMA opinions, meaning yesterday's CHMP endorsement does not automatically accelerate the UK timeline. However, a positive CHMP opinion is customarily treated as corroborating evidence for concurrent national reviews, and in practice the MHRA has tended to reach similar conclusions to the EMA on well-characterised compounds within months of a European Commission decision.

Research and procurement context

For UK laboratories procuring semaglutide reference standards or analogue peptides for in-vitro and mechanistic research, several points follow from this regulatory development.

Oral bioavailability as a formulation consideration. The 25 mg oral dose compared with the 2.4 mg injectable maintenance dose reflects the comparatively low bioavailability of peptides administered orally. Semaglutide is co-formulated with a salcaprozate sodium (SNAC) absorption enhancer in the oral product. Research groups studying oral peptide delivery systems should treat the OASIS clinical data as one of the few large-scale human datasets examining SNAC-facilitated absorption at scale; the mechanistic literature supporting this approach is now backed by an approved product's Phase 3 programme.

Purity benchmarks. The continued expansion of the approved semaglutide portfolio — now spanning five injectable doses (0.25 mg through 7.2 mg), a daily oral tablet, and the earlier cardiovascular, MASH, and heart failure label extensions — raises the benchmark for reference standards. The FDA has already issued warning letters to telehealth firms over compounded GLP-1 promotion and impurity concerns, and compounded semaglutide shipments are reported to be down approximately 90% year-on-year as the shortage designation lapsed and compounding authorisations were withdrawn. Research-grade semaglutide procured for legitimate analytical or mechanistic work should be sourced with a Certificate of Analysis verified against a recognised pharmacopoeial or in-house reference standard, with mass spectrometry confirmation of identity and HPLC purity ≥98% as a minimum threshold.

Competitor landscape. With two new semaglutide formulations advancing through EU and UK authorisation in parallel, the commercial pressure on Eli Lilly's tirzepatide (Mounjaro) and emerging oral small-molecule GLP-1 agonists will intensify. Injectable Mounjaro still produces approximately 22–25% mean weight loss at the top dose, compared with 20.7% for Wegovy HD and 13.6% for the oral pill, meaning the incremental differences between agents are now granular enough that label expansions, formulation convenience, and cardiovascular outcomes data — rather than headline efficacy alone — are likely to drive prescriber and payer decisions.

What to watch next

• European Commission decision on both formulations. A formal EC decision following a positive CHMP opinion typically arrives within approximately two months. A Q3 2026 EU launch for Wegovy HD in the single-dose pen is the company's stated expectation.
• MHRA decision on oral semaglutide. The late-2026 anticipated decision window will determine whether UK private prescribers can offer the oral formulation before year-end.
• Dysesthesia investigation outcome. The ongoing FDA review of the altered skin-sensation signal at 7.2 mg may result in prescribing information updates relevant to any research protocol involving the higher-dose form.
• CagriSema Phase 3 initiation. Novo Nordisk plans to initiate a high-dose CagriSema Phase 3 efficacy and safety trial in the second half of 2026, combining cagrilintide and semaglutide, which may further expand the semaglutide research toolkit available to laboratories.